A phase II trial of high dose cytarabine and fludarabine without anthracycline for patients with core binding factor acute myeloid leukaemia, measuring efficacy, safety and monitoring minimal residual disease (AMLM13)
收藏DataCite Commons2023-06-08 更新2024-07-13 收录
下载链接：
https://www.allg.org.au/datasets/amlm13/
下载链接
链接失效反馈官方服务：
资源简介：
HeSANDA 1.0.0
提供机构：
Australasian Leukaemia and Lymphoma Group (ALLG)
创建时间：
2023-06-08
